On November 18, 2026 INOVIO (NASDAQ: INO), a commercial-stage biotechnology company focused on developing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, reported that it has submitted a Conditional Marketing Authorization (CMA) application to the European Medicines Agency (EMA) for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, as a treatment for adults with RRP.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Building on the recent FDA approval of VOCERYQ, we believe there’s significant opportunity to transform the treatment paradigm for RRP in Europe, a region that currently has no approved non-surgical treatment options that target the root cause of RRP," said Dr. Michael Sumner, Chief Medical Officer of INOVIO. "We look forward to working closely with the EMA during the review and hope to ultimately provide RRP patients with a much-needed new treatment option that reduces the need for surgery."
"Clinicians and patients alike understand that every surgery matters, because every surgery puts a patient’s vocal cords at risk," said Frederik Dikkers, Professor emeritus of Otorhinolaryngology / Head and Neck Surgery at Amsterdam University Medical Center (Amsterdam UMC). "RRP affects patients around the world, and this submission is a meaningful step forward for those in Europe who have waited far too long for relief from this debilitating disease."
The CMA application is supported by a comprehensive set of preclinical, clinical, and manufacturing data, including results from INOVIO’s clinical studies for VOCERYQ published in in 2025 in Nature Communications and The Laryngoscope. An additional analysis of the data was published in October 2026 in The Laryngoscope under the title DNA Immunotherapy (INO-3107) Long-Term Efficacy Supported by Enhanced Immunogenicity in HPV-6/11 RRP.
The European Commission granted Orphan Drug designation to INO-3107, now VOCERYQ, for the treatment of RRP in 2023. INO-3107 also received an Advanced Therapy Medicinal Product (ATMP) Certification from the EMA’s Committee for Advanced Therapies (CAT) after review of chemistry, manufacturing and controls (CMC) and nonclinical data. This certification confirms that the data reviewed complies with the standards that would be used to evaluate a European marketing authorization application. INOVIO submitted the marketing authorization application using guidance from pre-submission meetings with EMA and the Rapporteurs. The CELLECTRA delivery device has a CE-mark in the EU, which allows INOVIO to commercialize the device in the EU and other geographies that recognize CE-marking.
The U.S. Food and Drug Administration (FDA) granted VOCERYQ accelerated approval on October 30, 2026 for adults with RRP to reduce the frequency of surgery. Continued approval for this indication may be contingent on verification and description of clinical benefit in a confirmatory study(ies). INOVIO expects to make VOCERYQ available to order and ship in the U.S. in approximately 60 days from the date of FDA approval, with full commercial launch expected in the first quarter of 2027.
About Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating disease caused primarily by HPV-6 and/or HPV-11. RRP is characterized by the development of small, wart-like growths, or papillomas, in the respiratory tract. While papillomas are generally benign, they can cause severe, life-threatening airway obstruction and respiratory complications. RRP can also significantly affect quality of life for patients by affecting the voice box, limiting the ability to speak effectively. Surgery to remove papillomas is the current standard of care for RRP; however, the papillomas often grow back. INOVIO’s market research to date with patients and healthcare professionals indicates that a reduction of even one surgery matters, because every surgery poses a significant risk of causing permanent damage to the vocal cords and comes with potential costs to the patient, including adverse impacts to both quality of life and finances. Based on ongoing analysis of claims data, INOVIO believes there is a prevalent population of at least 25,000 patients with RRP in the United States, with additional patients diagnosed each year.
About VOCERYQ
VOCERYQ is a plasmid DNA-based immunotherapy designed to reduce the frequency of surgery for adults with RRP. VOCERYQ targets the root cause of RRP by generating an immune response using DNA plasmids that encode for HPV-6 and HPV-11 antigens. VOCERYQ is administered using the CELLECTRA 5PSP delivery device. Following a standard-of-care surgical debulking of visible papilloma prior to the initial administration of VOCERYQ, no additional surgical intervention is required as part of the 9-week dosing regimen.
The FDA previously granted VOCERYQ both Orphan Drug and Breakthrough Therapy designations, and the European Commission granted INO-3107 Orphan Drug designation. The CELLECTRA delivery device has a CE-mark in the EU, which allows INOVIO to commercialize the device in the EU and other geographies that recognize CE-marking.
Learn more at www.voceryq.com.
INDICATION
VOCERYQ is indicated to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis.
This indication is approved under accelerated approval based on reduction in the frequency of surgical papilloma excisions. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory study(ies).
IMPORTANT SAFETY INFORMATION
Warnings & Precautions: Injection site reactions have occurred with VOCERYQ injection. Monitor patients for local site reactions for at least 30 minutes after treatment and manage accordingly.
Electroporation Related Adverse Reactions: Procedure-related effects including muscle contractions, transient bleeding, and vasovagal reactions may occur. Avoid use in patients with ipsilateral ICDs/pacemakers, metal implants or skin abnormalities at treatment site.
Adverse Reactions: Most common adverse reactions (incidence >5%) are injection site reactions, headache, fatigue, hypertension, nausea and dizziness.
Please go to www.voceryq.com for full Prescribing Information, including Patient Information.
(Press release, Inovio, NOV 18, 2026, View Source [SID1234674913])